leadf
logo-loader
viewXPhyto Therapeutics Corp.

XPhyto Therapeutics rapidly advances its drug delivery system for Parkinson's skin patches

The company said human pilot studies will take place in Europe during the third quarter, with a data read-out expected in the fourth quarter

XPhyto Therapeutics Corp. - XPhyto Therapeutics rapidly advances drug delivery system for Parkinson's skin patches
The patches are based on the neurological drug Rotigotine, which is approved for the treatment of Parkinson's disease and restless legs syndrome in Europe and the US

XPhyto Therapeutics Corp (CSE:XPHY) (OTCPINK:XPHYF) offered investors an update on its transdermal delivery system for the neurologic drug Rotigotine saying the “formula was locked” and the company is looking forward to clinical studies in the third quarter of 2020.

Vancouver-based XPhyto Therapeutics first revealed in June that its German subsidiary Vektor Pharma TF GmbH had finalized the formula for its skin patch to help Parkinson's disease sufferers ahead of human pilot studies.

According to the company, Vektor Pharma has now completed process implementation for the manufacture of its Rotigotine patches. “With process implementation complete, clinical sample manufacturing and analytical work will commence in Vektor’s EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany,” it said.

READ: XPhyto Therapeutics expedites development of 5-minute coronavirus saliva test in Germany

XPhyto said human bioavailability studies will take place in Europe during the third quarter, with a data read-out expected by the fourth quarter of this year.

“Our goal is the commercialization of a low-cost Rotigotine patch with superior bioavailability and adhesion properties,” XPhyto Therapeutics CEO Hugh Rogers said in a statement.

“Incorporating Rotigotine into Vektor’s novel transdermal drug delivery system platform is a major accomplishment. With the formula locked and manufacturing soon to commence, we look forward to the upcoming clinical studies,” he added.

Rotigotine is approved for the treatment of Parkinson's disease and restless legs syndrome in Europe and the United States. The active pharmaceutical ingredient is a generic off-patent drug that is typically formulated as a once-daily skin patch which provides a slow and constant supply of the drug over the course of 24 hours.

Global and European sales of Rotigotine patches last year came in at around $500 million, XPhyto noted.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: XPhyto Therapeutics Corp.

Price: 1.8 CAD

CSE:XPHY
Market: CSE
Market Cap: $104.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto German partner 3a Diagnostics planning to develop two saliva tests...

XPhyto (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to bring news their exclusive diagnostic partner, 3a-Diagnostics is developing a reverse transcription-polymerase chain reaction kit targeting COVID-19 with results in 25 minutes. Rogers telling Proactive they...

2 days, 12 hours ago

2 min read